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Background/introduction
One of the main limitations to the efficacy of chemother-
apy in the brain is the blood-brain barrier (BBB). Previous
pre-clinical studies have demonstrated that disruption of
the BBB using pulsed ultrasound in combination with an
ultrasound microbubble contrast agent can significantly
increase the concentration of chemotherapy agents in the
brain. Our group has developed an implantable, MR com-
patible ultrasound device for temporarily disrupting the
BBB. The safety of repeated disruption of the BBB using
such a device was previously demonstrated in a long-term
safety study in four non-human primates. The purpose of
this work was to determine the safety and potential effi-
cacy of temporarily disrupting the BBB in patients with
recurrent glioblastoma before chemotherapy administra-
tion in a first-in-man clinical trial.
Methods
A Phase 1/2a clinical trial to open the BBB in recurrent
glioblastoma patients was approved to start in July 2014
at the Hospital Pitie Salpetriere in Paris, France.
Participating patients will be implanted with an 11.5-mm
diameter biocompatible 1 MHz ultrasound transducer,
which will be fixed to the skull bone in a standard burr
hole, after which the skin will be closed. Once a month, the
device will be connected to an external generator system
using a transdermal needle connection, and patients will
receive a two minute pulsed ultrasound sonication (25,000
cycles/burst, 1 Hz) in combination with systemic adminis-
tration of an ultrasound contrast agent. BBB disruption will
be monitored immediately after sonication using dynamic
T1-weighted MR imaging using a gadolinium based MR
contrast agent to measure the permeability coefficient,
Ktrans, to quantify the magnitude of BBB disruption.
Systemic intravenous injection of Carboplatin (Area Under
the Curve 4-6) will be delivered immediately following MR
imaging. Patients will follow a progression of ultrasound
dose in which the pressure is increased from 0.5 to 0.8
MPa throughout the course of the study.
Results and conclusions
Pre-clinical results in a non-human primate demonstrated
an increase in concentration of carboplatin of 200-600%
after ultrasound-induced disruption of the BBB. Note that
this clinical trial was approved to begin in July 2014 and
thus no results were yet available in patients at the time of
abstract submission. The most recent results will be pre-
sented at the meeting. These studies will verify that the
BBB can be safely disrupted in patients with recurrent glio-
blastoma and will evaluate the tolerance and potential effi-
cacy of such an approach in combination with intravenous
administration of a chemotherapy regimen of carboplatin.
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